About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events

NEW YORK CITY, NY / ACCESS Newswire / September 6, 2025 / New to The Street, one of the nation's premier financial media platforms, today announced that Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, has re-signed for a comprehensive media partnership.

The expanded agreement includes long-form televised interviews, earned media placements, national TV commercials, and participation in exclusive AccreditedEvents.com investor forums. Through this collaboration, Acurx will continue to showcase its innovation and growth trajectory to millions of viewers and investors worldwide.

Strategic Media Partnership

The renewed partnership will bring Acurx to audiences across Bloomberg Television and Fox Business (as sponsored programming), New to The Street's 3.4M+ subscriber YouTube channel, iconic outdoor billboards in New York City's Times Square and Financial District, and social platforms including LinkedIn, X, Facebook, and Instagram.

Additionally, participation in AccreditedEvents.com will provide Acurx with direct access to targeted, qualified, and accredited investors through exclusive in-person and virtual events, further deepening the company's engagement with the investment community.

Executive Commentary

Vince Caruso, CEO & Co-Founder of New to The Street, stated: "We are proud to continue showcasing Acurx's pioneering work in antibiotic development. Our multi-platform approach - spanning national TV broadcasts, digital distribution, iconic outdoor billboards, and exclusive investor events - ensures predictable media exposure and helps companies like Acurx strengthen their visibility within the biotech investment community."

About Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP)

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP), and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).

Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials next year subject to obtaining appropriate financing. The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.

About New to The Street

For more than 16 years, New to The Street has been one of the longest-running U.S. and international sponsored and syndicated Nielsen-rated television programs, broadcasting weekly on Fox Business and Bloomberg Television as sponsored programming. With over 3.4 million YouTube subscribers, 500,000+ combined social followers, and iconic outdoor billboards in Times Square and New York City's Financial District, New to The Street provides companies with Predictable Media™ - a unique blend of long-form interviews, commercials, social media amplification, earned media pickups, and accredited investor access.
For more information, visit: www.newtothestreet.com.

Media Contact:
Monica Brennan
New to The Street
Monica@NewtoTheStreet.com

SOURCE: New to The Street



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.